Methylation of Ras association domain family protein 1, isoform a correlated with proliferation and drug resistance in hepatocellular carcinoma cell line SMMC-7721

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 5, 2007, Pages 683-689

  Zhao, Qiang Zi ^a   Dou, Ke Feng ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; Hepatocellular carcinoma; Methylation; RASSF1A

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; CISPLATIN; COMPLEMENTARY DNA; FLUOROURACIL; ISOPROTEIN; MITOMYCIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CANCER THERAPY; CELL GROWTH; CELL PROLIFERATION; CHEMOSENSITIVITY; CLINICAL ASSESSMENT; COLONY FORMATION; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; ENZYME ASSAY; EPIGENETICS; GENOME; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; METASTASIS; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN METHYLATION; TREATMENT RESPONSE; WILD TYPE; XENOGRAFT;

EID: 34247231422     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04676.x     Document Type: Article

References (30)

1. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 1996; 77: 2217-22.
2. Wilson JF. Liver cancer on the rise. Ann. Intern. Med. 2005; 142: 1029-32.
3. Baker EK, El-Osta A. The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer. Exp. Cell Res. 2003; 290: 177-94.
4. Dammann R, Yang G, Pfeifer GP. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res. 2001; 61: 3105-9.
5. Liu L, Zhang J, Bates S et al. A methylation profile of in vitro immortalized human cell lines. Int. J. Oncol. 2005; 26: 275-85.
6. Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am. J. Pathol. 2003; 163: 1371-8.
7. Kim DH, Kim JS, Ji YI et al. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res. 2003; 63: 3743-6.
8. Gao Y, Guan M, Su B, Liu W, Xu M, Lu Y. Hypermethylation of the RASSF1A gene in gliomas. Clin. Chim. Acta 2004; 349: 173-9.
9. Morabito F, Stelitano C, Callea I et al. In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features. Haematologica 1996; 81: 224-31.
10. Lambert E, Rees JK, Twentyman PR. Resistance circumvention strategies tested in clinical leukaemia specimens using the MTT colorimetric assay. Leukemia 1992; 6: 1063-71.
11. Carmichael J, Mitchell JB, DeGraff WG et al. Chemosensitivity testing of human lung cancer cell lines using the MTT assay. Br. J. Cancer 1988; 57: 540-7.
12. Miura Y, deFries R, Shimada H, Mitsuhashi M. Rapid cytocidal and cytostatic chemosensitivity test by measuring total amount of mRNA. Cancer Lett. 1997; 116: 139-44.
13. Horiuchi N, Nakagawa K, Sasaki Y et al. In vitro antitumor activity of mitomycin C derivative (RM-49) and new anticancer antibiotics (FK973) against lung cancer cell lines determined by tetrazolium dye (MTT) assay. Cancer Chemother. Pharmacol. 1988; 22: 246-50.
14. Nakada S, Aoki D, Ohie S et al. Chemosensitivity testing of ovarian cancer using the histoculture drug response assay: sensitivity to cisplatin and clinical response. Int. J. Gynecol. Cancer 2005; 15: 445-52.
15. Untch M, Sevin BU, Perras JP et al. Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay. Gynecol. Oncol. 1994; 53: 44-9.
16. Nyce J. Drug-induced DNA hypermethylation and drug resistance in human tumors. Cancer Res. 1989; 49: 5829-36.
17. Hogg RP, Honorio S, Martinez A et al. Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma. Eur. J. Cancer 2002; 38: 1585-92.
18. Waki T, Tamura G, Sato M, Motoyama T. Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples. Oncogene 2003; 22: 4128-33.
19. Muller HM, Widschwendter A, Fiegl H et al. DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res. 2003; 63: 7641-5.
20. Morrissey C, Martinez A, Zatyka M et al. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res. 2001; 61: 7277-81.
21. Yoon JH, Dammann R, Pfeifer GP. Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int. J. Cancer 2001; 94: 212-17.
22. Kim H, Kwon YM, Kim JS et al. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. J. Clin. Oncol. 2004; 22: 2363-70.
23. Shivakumar L, Minna J, Sakamaki T, Pestell R, White MA. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol. Cell. Biol. 2002; 22: 4309-18.
24. Song MS, Lim DS. Control of APC-Cdc20 by the tumor suppressor RASSF1A. Cell Cycle 2004; 3: 574-6.
25. Li WH, Cui Y, Zhu JR. [Methylated oligonucleotide inhibiting expression of human MRP2 and reversing multidrug resistance in hepatocellular carcinoma Cell HepG2]. Ai Zheng 2004; 23: 900-4.
26. Mollemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int. J. Cancer 2005; 113: 379-85.
27. Strathdee G, MacKean MJ, Illand M, Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 1999; 18: 2335-41.
28. Wang J, Lee JJ, Wang L et al. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin. Cancer Res. 2004; 10: 6119-25.
29. Fujiwara K, Fujimoto N, Tabata M et al. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin. Cancer Res. 2005; 11: 1219-25.
30. Pfeifer GP, Yoon JH, Liu L, Tommasi S, Wilczynski SP, Dammann R. Methylation of the RASSF1A gene in human cancers. Biol. Chem. 2002; 383: 907-14.